Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BSE5

UPID:
GDAH_HUMAN

ALTERNATIVE NAMES:
Arginase, mitochondrial; Guanidinobutyrase, mitochondrial; Guanidinopropionase, mitochondrial

ALTERNATIVE UPACC:
Q9BSE5; Q5TDH1; Q9H5J3

BACKGROUND:
The mitochondrial enzyme Guanidino acid hydrolase, recognized by alternative names such as Arginase, mitochondrial, Guanidinobutyrase, mitochondrial, and Guanidinopropionase, mitochondrial, is pivotal in converting guanidino acids to urea and amines. Its substrate specificity is directed towards compounds with short chains and negatively charged head groups, like taurocyamine, and guanidino propanoic and butanoic acids. This specificity underlines a cellular defense mechanism against the accumulation of toxic guanidino compounds and a role in L-arginine metabolism, despite its low efficiency in the latter.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Guanidino acid hydrolase, mitochondrial could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.